How often is Dupixent (dupilumab) administered?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dupixent Dosing Frequency

Dupixent (dupilumab) is most commonly dosed every 2 weeks (Q2W) for adults and adolescents, though dosing frequency varies significantly by indication, age, and weight, ranging from weekly to every 4 weeks. 1

Dosing by Indication

Atopic Dermatitis

Adults:

  • Initial loading dose: 600 mg (two 300 mg injections)
  • Maintenance: 300 mg every 2 weeks (Q2W) 1

Pediatric patients (6-17 years):

  • Weight-based dosing with variable intervals 1:
    • 15 to <30 kg: 300 mg every 4 weeks (Q4W) after 600 mg loading dose
    • 30 to <60 kg: 200 mg every 2 weeks (Q2W) after 400 mg loading dose
    • ≥60 kg: 300 mg every 2 weeks (Q2W) after 600 mg loading dose

Young children (6 months to 5 years):

  • No loading dose in this age group 1
  • 5 to <15 kg: 200 mg every 4 weeks (Q4W)
  • 15 to <30 kg: 300 mg every 4 weeks (Q4W)

Asthma

Adults and adolescents (≥12 years):

  • Standard: 200 mg or 300 mg every 2 weeks (Q2W) after loading dose 1
  • For oral corticosteroid-dependent asthma or comorbid moderate-to-severe AD: 300 mg every 2 weeks after 600 mg loading dose

Children (6-11 years):

  • 15 to <30 kg: 300 mg every 4 weeks (Q4W), no loading dose
  • ≥30 kg: 200 mg every 2 weeks (Q2W), no loading dose 1

Other Indications

  • Chronic rhinosinusitis with nasal polyps: 300 mg every 2 weeks (Q2W) 1
  • Eosinophilic esophagitis: Weight-based, ranging from 200-300 mg Q2W to 300 mg weekly (QW) for patients ≥40 kg 1
  • Prurigo nodularis: 300 mg every 2 weeks after 600 mg loading dose 1
  • COPD: 300 mg every 2 weeks 1

Important Clinical Considerations

Extended dosing intervals are increasingly recognized in clinical practice. Recent guidelines note that for pediatric atopic dermatitis, consideration should be given to spacing doses to every 4 weeks during childhood given the trauma of injection 2. The European Medicines Agency recommends 300 mg every 4 weeks rather than the FDA-recommended 200 mg every 2 weeks for children 30-60 kg, as efficacy data were relatively equivalent 2.

Real-world evidence demonstrates that nearly half of patients can successfully extend dosing intervals to Q3W, Q4W, or even up to Q12W without disease exacerbation 3. A systematic review confirms that extended dosing intervals (3-weekly or 4-weekly) maintain comparable efficacy to standard Q2W dosing in well-controlled patients 4.

Missed Dose Management

  • Q2W dosing: If missed, administer within 7 days and resume original schedule; if >7 days, wait until next scheduled dose 1
  • Q4W dosing: If missed, administer within 7 days and resume original schedule; if >7 days, administer dose and start new schedule from that date 1
  • Weekly dosing: Administer as soon as possible and start new weekly schedule from that date 1

Common Pitfalls

  • Don't assume all patients need Q2W dosing indefinitely—well-controlled patients may benefit from extended intervals with cost savings and reduced injection burden 3, 4
  • Weight-based dosing in children is critical—using adult dosing in pediatric patients can lead to under- or over-dosing
  • Loading doses are indication-specific—young children with AD (6 months-5 years) do NOT receive loading doses, unlike older age groups 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.